These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 30502788)

  • 21. Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients.
    Kiadaliri AA; Eliasson B; Gerdtham UG
    Health Qual Life Outcomes; 2015 Sep; 13():145. PubMed ID: 26374709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
    Pullenayegum EM; Chan KK; Xie F
    Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the health of the general population in England: how do the three- and five-level versions of EQ-5D compare?
    Feng Y; Devlin N; Herdman M
    Health Qual Life Outcomes; 2015 Oct; 13():171. PubMed ID: 26489956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishing utility values for the 22-item Sino-Nasal Outcome Test (SNOT-22) using a crosswalk to the EuroQol-five-dimensional questionnaire-three-level version (EQ-5D-3L).
    Crump RT; Lai E; Liu G; Janjua A; Sutherland JM
    Int Forum Allergy Rhinol; 2017 May; 7(5):480-487. PubMed ID: 28182331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimating an exchange rate between the EQ-5D-3L and ASCOT.
    Stevens K; Brazier J; Rowen D
    Eur J Health Econ; 2018 Jun; 19(5):653-661. PubMed ID: 28623464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using Discrete Choice Experiments with Duration to Model EQ-5D-5L Health State Preferences.
    Mulhern B; Bansback N; Hole AR; Tsuchiya A
    Med Decis Making; 2017 Apr; 37(3):285-297. PubMed ID: 27681988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dutch Tariff for the Five-Level Version of EQ-5D.
    M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
    Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing outcomes for cost-utility analysis in mental health interventions: mapping mental health specific outcome measure GHQ-12 onto EQ-5D-3L.
    Lindkvist M; Feldman I
    Health Qual Life Outcomes; 2016 Sep; 14(1):134. PubMed ID: 27644119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A French Value Set for the EQ-5D-5L.
    Andrade LF; Ludwig K; Goni JMR; Oppe M; de Pouvourville G
    Pharmacoeconomics; 2020 Apr; 38(4):413-425. PubMed ID: 31912325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mapping the COPD Assessment Test onto EQ-5D.
    Hoyle CK; Tabberer M; Brooks J
    Value Health; 2016 Jun; 19(4):469-77. PubMed ID: 27325339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Methods for the Mapping of Utilities Using Mixture Models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma.
    Gray LA; Hernández Alava M; Wailoo AJ
    Value Health; 2018 Jun; 21(6):748-757. PubMed ID: 29909881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The EQ-5D-5L valuation study in Korea.
    Kim SH; Ahn J; Ock M; Shin S; Park J; Luo N; Jo MW
    Qual Life Res; 2016 Jul; 25(7):1845-52. PubMed ID: 26961008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visual and health outcomes, measured with the activity inventory and the EQ-5D, in visual impairment.
    Macedo AF; Ramos PL; Hernandez-Moreno L; Cima J; Baptista AMG; Marques AP; Massof R; Santana R
    Acta Ophthalmol; 2017 Dec; 95(8):e783-e791. PubMed ID: 28371261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating.
    Thompson NR; Lapin BR; Katzan IL
    Pharmacoeconomics; 2017 Nov; 35(11):1167-1176. PubMed ID: 28710740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating quality weights for EQ-5D (EuroQol-5 dimensions) health states with the time trade-off method in Taiwan.
    Lee HY; Hung MC; Hu FC; Chang YY; Hsieh CL; Wang JD
    J Formos Med Assoc; 2013 Nov; 112(11):699-706. PubMed ID: 24183199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predicting the EuroQol Group's EQ-5D index from CDC's "Healthy Days" in a US sample.
    Jia H; Zack MM; Moriarty DG; Fryback DG
    Med Decis Making; 2011; 31(1):174-85. PubMed ID: 20375418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EQ-5D-3L as a health measure of Brazilian adult population.
    Menezes Rde M; Andrade MV; Noronha KV; Kind P
    Qual Life Res; 2015 Nov; 24(11):2761-76. PubMed ID: 25896666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
    Doble B; Lorgelly P
    Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An Australian discrete choice experiment to value eq-5d health states.
    Viney R; Norman R; Brazier J; Cronin P; King MT; Ratcliffe J; Street D
    Health Econ; 2014 Jun; 23(6):729-42. PubMed ID: 23765787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.